CALT Calliditas Therapeutics: Nilai Akuntansi saben Saham

Calliditas Therapeutics (CALT) revenue relies on a single orphan drug, yet concentration risks are mitigated by its integration into a global medical holding. The book value per share trend reflects the issuer's tangible assets, and this metric has reached the level of 0.37. High margins coupled with low personnel costs are offset by threats from low-cost generics and a potential revision of insurance reimbursement terms.

Investors are assessing the resilience of Calliditas Therapeutics (CALT) through the net asset value per share after deducting liabilities. By analyzing the book value per share, one can track the transformation of profit into capital, which, for a developer of orphan drugs, confirms a financial foundation secured by patent exclusivity and guaranteed demand for lifelong kidney therapy.